LEGN
NASDAQLegend Biotech Corporation
Price$18.45-0.75 (-3.88%)
01:30 PM07:45 PM
News · 26 weeks59+143%
2026-04-192026-10-11
Mix3690d
- SEC Filings12(33%)
- Insider12(33%)
- Other7(19%)
- Analyst2(6%)
- Leadership2(6%)
- Earnings1(3%)
Latest news
25 items- SECSEC Form 6-K filed by Legend Biotech Corporation6-K - Legend Biotech Corp (0001801198) (Filer)
- PRLegend Biotech Announces U.S. FDA Clearance of IND Application for LB2501, an Investigational CD19/CD20 In Vivo CAR-T TherapyLB2501 is an off-the-shelf in vivo CAR-T therapy designed to generate dual-targeting CD19/CD20 CAR-T cells directly within the patient after a single infusion, making it the first known dual-targeting in vivo CAR-T therapy to receive FDA IND clearance IND clearance supports planned U.S. Phase 1/2 study and advances Legend Biotech’s in vivo cell engineering platform BRIDGEWATER, N.J., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, today announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for LB2501, an investigational in vivo CAR-T therapy designe
- SECSEC Form 6-K filed by Legend Biotech Corporation6-K - Legend Biotech Corp (0001801198) (Filer)
- SECSEC Form S-8 filed by Legend Biotech CorporationS-8 - Legend Biotech Corp (0001801198) (Filer)
- INSIDERDirector Sanders Corazon (Corsee) D. sold $258,920 worth of Ordinary Shares (27,370 units at $9.46), decreasing direct ownership by 34% to 52,731 units (SEC Form 4)4 - Legend Biotech Corp (0001801198) (Issuer)
- PRLegend Biotech Launches Inaugural ELITE Grant Program to Advance the Next Generation of CAR-T Innovation in Multiple MyelomaAnnual program will award funding to early-career healthcare professionals advancing research, education, and innovation in multiple myeloma BRIDGEWATER, N.J., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, today announced the launch of its inaugural Emerging Leadership & Innovation in Cell Therapy Excellence (ELITE) Program, an annual grant initiative designed to recognize and support early-career healthcare professionals advancing novel cell therapy approaches for the treatment of multiple myeloma. Applications are open through November 20, 2026. "At Legend Biotech, we believe that advancing the future of ce
- SECSEC Form 144 filed by Legend Biotech Corporation144 - Legend Biotech Corp (0001801198) (Subject)
- INSIDERDirector Heyman Tomas J. was granted 20,986 units of Ordinary Shares, increasing direct ownership by 64% to 53,720 units (SEC Form 4)4 - Legend Biotech Corp (0001801198) (Issuer)
- INSIDERDirector Casey Patrick John was granted 20,986 units of Ordinary Shares, increasing direct ownership by 43% to 69,590 units (SEC Form 4)4 - Legend Biotech Corp (0001801198) (Issuer)
- INSIDERDirector Mao Li was granted 20,986 units of Ordinary Shares, increasing direct ownership by 47% to 65,316 units (SEC Form 4)4 - Legend Biotech Corp (0001801198) (Issuer)
- INSIDERDirector Ji Darren Xiaohui was granted 28,330 units of Ordinary Shares, increasing direct ownership by 44% to 92,103 units (SEC Form 4)4 - Legend Biotech Corp (0001801198) (Issuer)
- INSIDERDirector Sanders Corazon (Corsee) D. was granted 20,986 units of Ordinary Shares, increasing direct ownership by 36% to 80,101 units (SEC Form 4)4 - Legend Biotech Corp (0001801198) (Issuer)
- INSIDERDirector Salovey Peter was granted 28,330 units of Ordinary Shares, increasing direct ownership by 106% to 55,096 units (SEC Form 4)4 - Legend Biotech Corp (0001801198) (Issuer)
- SECSEC Form 6-K filed by Legend Biotech Corporation6-K - Legend Biotech Corp (0001801198) (Filer)
- PRLegend Biotech Presents CARVYKTI Data Showing Half of Patients with RRMM Remained Progression-Free and Alive Five Years After a Single InfusionFive-year overall survival rate was 69.2%, adding to growing long-term evidence supporting the curative potential of CARVYKTI in earlier-line RRMM BRIDGEWATER, N.J., Sept. 25, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, today announced five-year follow-up data from CARTITUDE-2 Cohort A (n=20) evaluating CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) in patients with relapsed/refractory multiple myeloma (RRMM) after one to three prior lines of therapy after a median follow-up of 60.7 months. These data were presented today at the 2026 International Myeloma Society (IMS) Annual Meeting in Glasgow, Scotland (Abstract
- SECSEC Form 6-K filed by Legend Biotech Corporation6-K - Legend Biotech Corp (0001801198) (Filer)
- INSIDERChief Financial Officer Santos Carlos E sold $49,630 worth of Ordinary Shares (5,430 units at $9.14) and was granted 19,676 units of Ordinary Shares (SEC Form 4) to satisfy withholding obligation4 - Legend Biotech Corp (0001801198) (Issuer)
- INSIDERChief Executive Officer Zhang Ingrid was granted 1,131,860 units of Ordinary Shares (SEC Form 4)4 - Legend Biotech Corp (0001801198) (Issuer)
- INSIDERSEC Form 3 filed by new insider Zhang Ingrid3 - Legend Biotech Corp (0001801198) (Issuer)
- SECSEC Form 6-K filed by Legend Biotech Corporation6-K - Legend Biotech Corp (0001801198) (Filer)
- PRLegend Biotech Appoints Ingrid Zhang as Chief Executive OfficerBRIDGEWATER, N.J., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) ("Legend Biotech" or the "Company"), a global leader in cell therapy, today announced that its Board of Directors has appointed Ingrid Zhang as Chief Executive Officer, effective September 15, 2026. Ingrid Zhang succeeds Alan Bash, who has served as Interim Chief Executive Officer since July 2026 and will resume his role as President, CARVYKTI. Ingrid Zhang is an accomplished global biopharmaceutical executive with deep experience leading commercial organizations, driving business growth, and advancing innovative medicines. Most recently, she served as Chief Commercial Officer for Novartis Inter
- SECSEC Form 6-K filed by Legend Biotech Corporation6-K - Legend Biotech Corp (0001801198) (Filer)
- PRLegend Biotech to Present Updated Long-Term and Real-World Evidence from CARVYKTI Clinical Program at the International Myeloma Society Annual MeetingUpdated long-term follow-up data will be presented from CARTITUDE-2 Cohort A in patients with lenalidomide-refractory multiple myeloma after 1-3 prior lines of therapyReal-world evidence and post-authorization safety study findings will also be presented BRIDGEWATER, N.J., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, today announced that data from CARTITUDE-2 and real-world evidence will be presented at the 23rd International Myeloma Society (IMS) Annual Meeting, taking place September 23-26, 2026, in Glasgow, Scotland. The presentations will include updated long-term follow-up data from the CARTITUDE-2 clin
- PRLegend Biotech to Participate in the Morgan Stanley Global Healthcare ConferenceBRIDGEWATER N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Alan Bash, interim Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference in New York, NY on Tuesday, September 15, 2026, at 2:35 p.m. ET. The live webcast will be available to investors and other interested parties by accessing the Investor Relations section of the Legend Biotech website. The webcast replay will be available approximately 48 hours after the webcast. ABOUT LEGEND BIOTECH With over 3,000 employees, Legend Biotech is the largest standalone cell therapy
- INSIDERInterim CEO Bash Alan was granted 4,908 units of Ordinary Shares, increasing direct ownership by 16% to 35,142 units (SEC Form 4)4 - Legend Biotech Corp (0001801198) (Issuer)
LEGN FAQ
7 questionsWhat does Legend Biotech Corporation do?
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in North America and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in relapsed and refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates targeting various cancers, including non-hodgkins...Where does LEGN stock trade?
Legend Biotech Corporation (LEGN) is listed on NASDAQ.What sector and industry is LEGN in?
Legend Biotech Corporation operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Legend Biotech Corporation go public?
Legend Biotech Corporation (LEGN) completed its IPO in 2020.What are analysts saying about LEGN?
Legend Biotech Corporation has had 8 recent analyst actions on file. The most recent action was from Oppenheimer: Perform on 2026-08-12. Recent price targets range from $2100.00 to $4000.00.What companies are similar to LEGN?
Notable peers in the same industry include SQZ (SQZ Biotechnologies Company), EDSA (Edesa Biotech Inc.), BBI (Brickell Biotech Inc.). Compare LEGN side-by-side with any of them on Quantisnow.How can I track LEGN on Quantisnow?
Quantisnow aggregates Legend Biotech Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LEGN to receive live email and push alerts on every new disclosure.